Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 5 (5)

From GxPlex

Revision as of 17:29, 15 July 2026 by imported>GxPlexBot (Import from GxPlex Excel)
Jump to: navigation, search



Document information
Reference GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004
Validity area GBR
Scope(s) HM
Document name The Medicines for Human Use (Clinical Trials) Regulations 2004
Version / Revision 01-May-2004
Status Current
Document type Legal act
Language(s) EN
Description The Medicines for Human Use (Clinical Trials) Regulations 2004
Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 6 — Unit 6.1.2
Scope HM
Document part Schedule 5

(5)

Language EN
Original entry by Florian Adragna
Contributors
Tags Authorisation revocation, Temporary halt, Early termination, Competent authority, Amendment
Comment Procedural provisions on refusal or amendment of authorisation

Content

PROCEDURAL PROVISIONS RELATING TO THE REFUSAL OR AMENDMENT OF, OR IMPOSITION OF CONDITIONS RELATING TO, CLINICAL TRIAL AUTHORISATION AND THE SUSPENSION OR TERMINATION OF CLINICAL TRIALS 1.— […] (5) In the case of a notice to suspend or terminate a trial, the licensing authority shall, after considering the report of the appropriate committee or the Commission, confirm or revoke the notice. [...] 3.— [...] (4) The decisions to which this paragraph applies are decisions of the licensing authority— (a)to confirm— (i)that they have grounds for not accepting a request for authorisation or an amendment to the clinical trial authorisation, (ii)their decision to impose a condition, or (iii)the notice to suspend or terminate the trial,against the advice of the Medicines Commission under paragraph 1(2);